Chesley Taft & Associates’s iShares iBonds Dec 2032 Term Corporate ETF IBDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.37M Hold
56,900
– – 0.05% 184
2026
Q2
$1.43M Buy
56,900
+1,900
+3% +$47.9K 0.06% 187
2026
Q1
$1.39M Buy
55,000
+3,000
+6% +$76.5K 0.06% 190
2025
Q4
$1.33M Buy
52,000
+6,100
+13% +$156K 0.05% 191
2025
Q3
$1.18M Buy
45,900
+17,100
+59% +$434K 0.05% 191
2025
Q2
$728K Buy
28,800
+19,300
+203% +$479K 0.03% 230
2025
Q1
$237K Buy
+9,500
New +$235K 0.01% 319

Other funds holding IBDX

Chesley Taft & Associates's IBDX Position: Q3 2026 in Review

Chesley Taft & Associates held its iShares iBonds Dec 2032 Term Corporate ETF (IBDX) position steady in Q3 2026 at 56,900 shares worth $1.37M. The position accounts for 0.05% of the portfolio, ranked #184.

Chesley Taft & Associates first reported a position in IBDX in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.43M in Q2 2026. 168 funds tracked by Wall St. Rank hold IBDX as of Q3 2026.

  • Chesley Taft & Associates held 56,900 shares of iShares iBonds Dec 2032 Term Corporate ETF worth $1.37M as of Q3 2026.
  • Chesley Taft & Associates left its iShares iBonds Dec 2032 Term Corporate ETF share count unchanged in Q3 2026.
  • iShares iBonds Dec 2032 Term Corporate ETF made up 0.05% of Chesley Taft & Associates's portfolio in Q3 2026, its #184 holding.
  • Chesley Taft & Associates first reported a position in iShares iBonds Dec 2032 Term Corporate ETF in Q1 2025 and has held it in 7 quarters since.
  • Chesley Taft & Associates's iShares iBonds Dec 2032 Term Corporate ETF position peaked at $1.43M in Q2 2026.
  • 168 funds tracked by Wall St. Rank held iShares iBonds Dec 2032 Term Corporate ETF as of Q3 2026.

Based on Chesley Taft & Associates's 13F filing for Q3 2026, filed 13 Oct 2026.